Suset Almuinas de Armas, MD1ª;
Aala Dweik, MD2ª;
Carlos Carracedo Uribe, MD3; Atif M Hussein, MD, MMM, FACP4*
1,2PGY2 Internal Medicine Residency Memorial Healthcare
System
3PGY5 Hematology/Oncology Fellowship Memorial Healthcare
System/Memorial Cancer Institute
4Program Director, Hematology Oncology Fellowship Program
Memorial Healthcare System/Memorial Cancer Institute
ªThese
authors contributed equally to this work
*For Correspondence
ahussein@mhs.net
Lymphoid and myeloid
malignancies, including lymphomas and leukemias, represent a significant
portion of hematologic cancers globally, with distinct pathophysiology,
prognosis, and therapeutic approaches. Non-Hodgkin lymphomas (NHL), notably
diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and
follicular lymphoma (FL), demonstrate variable clinical behaviors and treatment
paradigms shaped by molecular classification and emerging targeted therapies.
Acute leukemias, particularly acute promyelocytic leukemia (APL), have seen
remarkable improvements in survival with the advent of differentiation
therapies. Chronic leukemias—chronic lymphocytic leukemia (CLL) and chronic
myeloid leukemia (CML)—are now highly controllable chronic diseases in many
cases, with tyrosine kinase inhibitors revolutionizing CML outcomes. This
chapter provides an updated, concise review of these malignancies tailored for
the practicing internist, emphasizing recent advances that influence diagnosis,
risk stratification, and initial management.
Keywords
Hodgkin Lymphomas, Non-Hodgkin Lymphomas, Chronic Leukemia, Acute Promyelocytic Leukemia
Download PDF